Efruxifermin is under clinical development by Akero Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Efruxifermin’s likelihood of approval (LoA) and phase transition for Non-Alcoholic Steatohepatitis (NASH) took place on 12 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Efruxifermin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Efruxifermin overview

Efruxifermin (AKR-001) is under development for the treatment of non-alcoholic steatohepatitis (NASH), type 2 diabetes and cirrhosis due to NASH. The drug candidate is a long-acting fibroblast growth factor 21 (FGF21) analog. It is a fusion protein obtained by the fusion of Fc domain of human IgG1 to the N-terminus of human mature FGF21 via a linker peptide. The drug candidate acts by targeting fibroblast growth factor receptors 1, 2, 3. It is administered through subcutaneous route. It was also under development for obesity.

Akero Therapeutics overview

Akero Therapeutics is a clinical-stage cardio-metabolic company. The company develops transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero’s lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. It also develop medicines for the treatment of metabolic diseases. The company is funded by Atlas Venture, ATP, venBio Partners and Versant Ventures. The company has offices in Massachusetts and California. Akero Therapeutics is headquartered in California, US.

Quick View Efruxifermin LOA Data

Report Segments
  • Innovator
Drug Name
  • Efruxifermin
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
Key Developers
  • Sponsor Company: Akero Therapeutics
  • Originator: Amgen
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.